Logo
TMO logo
Thermo Fisher Scientific Inc.
TMO
578.71 (-0.24%) 1.42
Health Care
Life Sciences Tools and Services
Thermo Fisher Scientific Inc. provides life sciences solutions analytical instruments specialty diagnostics and laboratory products and biopharma services in the North America Europe Asia-Pacific and internationally. The company’s Life Sciences Solutions segment offers reagents instruments and consumables for biological and medical research discovery and production of drugs and vaccines as well as diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments consumables software and services for pharmaceutical biotechnology academic government environmental and other research and industrial markets as well as clinical laboratories. The company’s Specialty Diagnostics segment includes clinical diagnostics offering liquid ready-to-use and lyophilized immunodiagnostic reagent kits as well as calibrators controls protein detection assays and instruments; immunodiagnostics offers develops manufactures and markets complete blood test systems to support the clinical diagnosis and monitoring of allergy asthma and autoimmune diseases; microbiology offers dehydrated and prepared culture media collection and transport systems instrumentation and consumables; transplant diagnostics products include human leukocyte antigen typing and testing for organ transplant market; and healthcare market channel offers consumables diagnostic kits and reagents equipment instruments solutions and services. Its Laboratory Products and Biopharma Services segment provides laboratory products research and safety market channel and pharma services and clinical research. It offers products and services through a direct sales force customer-service professionals electronic commerce and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham Massachusetts.

Quality Checklist 5/8

5Y Shares Out Change < 0%
Debt/Equity < 1
Current Ratio > 1
Net Margin > 10%
Est. EPS Growth > 5%
ROIC > 10%
Quick Ratio > 1
Past Net Income CAGR > 0%
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $217.43(B)
EV: $249.70(B)
Total Equity: $51.15(B)
Earnings date: Jan-29-2026
P/E: 33.37
Forward P/E: 25.46
P/FCF: 35.57
P/S: 5.01
P/B: 4.26
EPS: $17.3
EPS (fwd): $22.7
FCF/share: $16.3
Revenue/share: $115.4
Book value/share: $135.8
ROIC: 7.7%
ROA: 6.5%
ROE: 13.1%
Debt/Equity: 0.70
Current Ratio: 1.50
Gross margin: 41.4%
Operating margin: 18.4%
Net margin: 15.0%
Dividend/share: $1.7
Div. yield: 0.29%
All Valuation Overview Growth Financials & KPIsCompetitors & Peer Comparison Ownership Tools

TMO Valuation & Price Targets

Current Price
$579

Favorite Valuation Methods

PEvaluation
N/A
Analyst targets
N/A
DCF (2-stage)
N/A

More Valuation Methods

DCF (simple)
N/A
N/A
DCF (exit mult.)
N/A
N/A
DDM
N/A
N/A
EPS growth
N/A
N/A
Revenue growth
N/A
N/A
Peter Lynch FV
N/A
N/A
Graham No.
N/A
N/A

PEvaluation

37% overvalued
Low
$272
Mid
$363
High
$453
Current price
$579
Fair P/E
Margin of safety
EPS
Market Model
Shares outstan...ROICRevenue growthDebt/FCFAssets/Liabili...
Economic moat: Medium

EPS Estimates

LowAvgHigh#
FY+122.522.722.825
FY+224.024.625.926
FY+326.127.228.416
FY+430.030.732.35
FY+532.434.336.93

Analyst Price Targets

7% undervalued
Low
$533
Mid
$620
High
$675
Current price
$579

Analyst Recommendations

Strong Buy4
Buy13
Hold8
Sell0
Strong Sell0

2-stage DCF

First Stage Duration: 5 Years
Starting Free Cash Flow
First Stage Growth Rate
LowMidHigh
Terminal Growth Rate
LowMidHigh
Discount Rate

Discounted Cash Flow

Forecast years: 5 Years
Terminal Growth Rate
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Discounted Cash Flow (exit mult.)

Forecast years: 5 Years
Exit FCF Multiple
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Dividend Discount Model

Annual Dividend
First Stage Length (Years): 0 Years
First Stage Growth Rate
Final Growth Rate
Discount Rate

EPS Growth

Forecast years: 5 Years
Starting EPS
EPS Growth Rate
LowMidHigh
Final P/E
LowMidHigh
Discount Rate

Revenue Growth Valuation

Forecast Years: 10 Years
Base Revenue
Revenue Growth Rate
LowMidHigh
Final Net Margin
LowMidHigh
Final P/E Ratio
LowMidHigh
Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Government Bond Rate

TTM Financials

Income (TTM)

RevenueGrossNet
Revenue$43.74(B)
Gross profit$18.10(B)
EBITDA$10.84(B)
Net income$6.57(B)
Gross margin41.4%
Operating margin18.4%
Net margin15.0%
Shares outstanding375.71(M)

Balance sheet

Cash & ST inv.Other ST assetsLong term assetsCurrent liabilitiesLong term debtOther LT liabilitiesEquity
Total assets$103.02(B)
Current assets$22.30(B)
Total liabilities$51.87(B)
Current liabilities$14.89(B)
Cash & Short-term inv.$3.55(B)
Long-term debt$31.66(B)
Total intangibles$65.53(B)
PP&E$10.18(B)

Cash flow (TTM)

CFOCFICFF
FCF$6.11(B)
CapEx$-1.54(B)
Dividends paid$-623.00(M)
Stock issued$0
Stock repurchased$-3.96(B)
Stock-based comp.$305.00(M)
Debt issued$3.94(B)
Debt repaid$-4.72(B)

Per share data (TTM)

Price: $579
Revenue: $115 (5.0x | 19.9%) Gross profit: $48.2 (12.0x | 8.3%) Earnings: $17.3 (33.4x | 3.0%)
FCF: $16.3 (35.6x | 2.8%) Stock-based Comp.: $0.81 (712.9x | 0.1%) CapEx.: $4.10 (141.2x | 0.7%) Dividend: $1.68 (344.5x | 0.3%)
Total Assets: $274 (2.1x | 47.4%) Total Liabilities: $138 (4.2x | 23.9%) Book Value: $136 (4.3x | 23.5%) Cash & ST inv.: $9.44 (61.3x | 1.6%) Debt: $84.3 (6.9x | 14.6%)
Earnings FY+1: $22.7 (25.5x | 3.9%) Earnings FY+2: $24.6 (23.5x | 4.3%) Earnings FY+3: $27.2 (21.3x | 4.7%) Earnings FY+4: $30.7 (18.8x | 5.3%) Earnings FY+5: $34.3 (16.9x | 5.9%)
FCF FY+1: $17.6 (32.9x | 3.0%) FCF FY+2: $22.5 (25.8x | 3.9%) FCF FY+3: $24.6 (23.6x | 4.2%) FCF FY+4: $26.6 (21.7x | 4.6%) FCF FY+5: $30.0 (19.3x | 5.2%)

Summary

Growth Estimates

Revenue

CAGR: 5.0%
FY+1FY+2FY+3FY+4FY+5
FY+1$44.26(B)
FY+2(+5.1%)$46.51(B)
FY+3(+5.5%)$49.08(B)
FY+4(+5.2%)$51.61(B)
FY+5(+4.1%)$53.70(B)

Net Income

CAGR: 8.8%
FY+1FY+2FY+3FY+4FY+5
FY+1$8.59(B)
FY+2(+7.5%)$9.24(B)
FY+3(+8.7%)$10.04(B)
FY+4(+10.3%)$11.07(B)
FY+5(+8.9%)$12.06(B)

EPS

CAGR: 10.9%
FY+1FY+2FY+3FY+4FY+5
FY+1$22.73
FY+2(+8.4%)$24.64
FY+3(+10.3%)$27.17
FY+4(+13.0%)$30.71
FY+5(+11.8%)$34.32

FCF per share

CAGR: 14.3%
FY+1FY+2FY+3FY+4FY+5
FY+1$17.59
FY+2(+27.7%)$22.47
FY+3(+9.3%)$24.57
FY+4(+8.3%)$26.62
FY+5(+12.7%)$30.00

Historical Financials

Showing limited histrical data.
TTM (Y)TTM (Q)FYFQ
Income(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.010.0(B)20.0(B)30.0(B)40.0(B)
Revenue Operating Income Net IncomeCOGSGross ProfitTotal OpEx.R&DSG&AInterest ExpenseInterest IncomeOther Non-operating IncomePre-tax incomeIncome tax
Cash flow(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.02.0(B)4.0(B)6.0(B)
Stock-based Comp. FCFCFONet IncomeD&AChange in Working CapitalCFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures
Balance sheet(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.020.0(B)40.0(B)60.0(B)80.0(B)100.0(B)
Total Assets Total LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EIntangible AssetsGoodwillCurrent liabilitiesShort-Term DebtAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity
Per share data(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.05.010.015.020.0
EPS (Basic) FCF/Share Dividend/ShareEPS (Diluted)Book value/ShareCash & ST inv./ShareDebt/Share
Ratios(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.010.020.030.0
P/E P/S EV/EarningsP/FCFP/BEV/FCFDebt/EquityPayout ratio
Margins(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0%10%20%30%40%50%
Net Income Margin Operating Margin Gross MarginEBITDA MarginFCF Margin
Returns(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0%2%4%6%8%10%12%14%
ROIC ROAROCEROE
Shares outstanding(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.0100.0(M)200.0(M)300.0(M)
Shares (Basic)Shares (Diluted)
Market Cap.(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.050.0(B)100.0(B)150.0(B)200.0(B)
Market Cap.

TMO vs Peers

Similar Companies

Ownership

Major holders

*Excludes indirect insider ownership

Insiders: 0.15%
Institutions: 92.77%
Other: 7.08%

Institutional ownership

9.01% Vanguard Group Inc7.89% Blackrock Inc.4.39% State Street Corporati...3.43% Morgan Stanley2.74% Capital World Investor...2.17% Geode Capital Manageme...2.02% FMR, LLC1.94% JPMORGAN CHASE & CO1.58% Franklin Resources, In...1.49% NORGES BANK56.11% Others

Trading Summary

In the past year, insiders have bought $11038 worth of the company's stock, and sold $80.40(M).

Congress members have bought between $81011 - $340000 worth of the company's stock, and sold between $113015 - $470000.

Insider transactions

$0.002025-12$0.00
$7.57(M)2025-11$0.00
$14.14(M)2025-10$0.00
$2002012025-09$0.00
$13.60(M)2025-08$0.00
$1919922025-07$0.00
$0.002025-06$0.00
$1644442025-05$0.00
$1289792025-04$0.00
$12.28(M)2025-03$0.00
$21.50(M)2025-02$0.00
$0.002025-01$0.00
$10.62(M)2024-12$11038
DateSharesTotal ($)Price ($)NameTitle
Grant2025-11-102,975845,688284.3PETTITI GIANLUCAOfficer
Sell2025-11-102,9751,725,500580.0PETTITI GIANLUCAOfficer
Grant2025-11-078,4752,152,565254.0BRITT LISA POfficer
Sell2025-11-0710,2255,844,850571.6BRITT LISA POfficer
Grant2025-10-2724,3546,185,672254.0CASPER MARC NChief Executive Officer
Sell2025-10-2724,35413,914,104571.3CASPER MARC NChief Executive Officer
Sell2025-10-24400229,660574.1PETTITI GIANLUCAOfficer
Grant2025-09-05400101,596254.0CASPER MARC NChief Executive Officer
Sell2025-09-05400200,201500.5CASPER MARC NChief Executive Officer
Grant2025-08-2938597,786254.0HOLMES JOSEPH R.Officer
Sell2025-08-29385189,662492.6HOLMES JOSEPH R.Officer
Grant2025-08-2210,0002,539,900254.0CASPER MARC NChief Executive Officer
Sell2025-08-2210,0005,009,586501.0CASPER MARC NChief Executive Officer
Grant2025-08-20496125,979254.0CASPER MARC NChief Executive Officer
Sell2025-08-20496248,046500.1CASPER MARC NChief Executive Officer
Grant2025-08-0718,0004,571,820254.0CASPER MARC NChief Executive Officer
Sell2025-08-0718,0008,153,783453.0CASPER MARC NChief Executive Officer
Sell2025-07-25400191,992480.0PETTITI GIANLUCAOfficer
Grant2025-06-025,41700.0SHROPSHIRE THOMAS B JR.General Counsel
Grant2025-05-2156500.0CHANDY RUBY RDirector
Grant2025-05-2156500.0HARRIS C. MARTIN M.D.Director
Grant2025-05-2156500.0WEISLER DION JDirector
Grant2025-05-2156500.0KEITH R ALEXANDRADirector
Grant2025-05-2156500.0JACKS TYLERDirector
Grant2025-05-2156500.0SPAR DEBORA LDirector
Grant2025-05-2156500.0CHAI NELSON JDirector
Grant2025-05-2156500.0LYNCH KAREN S.Director
Grant2025-05-2156500.0SPERLING SCOTT MDirector
Grant2025-05-2156500.0JOHNSON JENNIFER MDirector
Grant2025-05-2156500.0MULLEN JAMES CHARLESDirector
Sell2025-05-12400164,444411.1PETTITI GIANLUCAOfficer
Sell2025-04-28300128,979429.9PETTITI GIANLUCAOfficer
Sell2025-03-103,7752,010,537532.6BOXER MICHAEL AGeneral Counsel
Grant2025-03-0518,0004,571,820254.0CASPER MARC NChief Executive Officer
Sell2025-03-0518,0009,326,854518.2CASPER MARC NChief Executive Officer
Sell2025-03-031,780945,038530.9SHAFER MICHAEL DOfficer
Grant2025-02-2418,3003,855,444210.7LOWERY FREDERICK M.Officer
Sell2025-02-2418,3009,732,123531.8LOWERY FREDERICK M.Officer
Grant2025-02-1963100.0HOLMES JOSEPH R.Officer
Grant2025-02-196,31500.0SHAFER MICHAEL DOfficer
Grant2025-02-196,68100.0LOWERY FREDERICK M.Officer
Grant2025-02-198,87900.0PETTITI GIANLUCAOfficer
Grant2025-02-199,64900.0LAGARDE MICHELChief Operating Officer
Grant2025-02-197,94200.0WILLIAMSON STEPHENChief Financial Officer
Grant2025-02-193,48200.0BRITT LISA POfficer
Grant2025-02-192,61100.0BOXER MICHAEL AGeneral Counsel
Grant2025-02-1923,73600.0CASPER MARC NChief Executive Officer
Grant2025-02-199500.0LYNCH KAREN S.Director
Sell2025-02-19168,449528.1CHAI NELSON JDirector
Grant2025-02-142,75000.0CASPER MARC NChief Executive Officer
Grant2025-02-0419,6504,990,904254.0WILLIAMSON STEPHENChief Financial Officer
Sell2025-02-0419,65011,580,924589.4WILLIAMSON STEPHENChief Financial Officer
Sell2025-02-04300175,677585.6PETTITI GIANLUCAOfficer
Buy2024-12-092011,038551.9CHAI NELSON JDirector
Grant2024-12-0519000.0BOXER MICHAEL AGeneral Counsel
Sell2024-12-0320,00010,624,559531.2CASPER MARC NChief Executive Officer

Congressional trading

$0.002025-12$0.00
$0.002025-11$0.00
$0.002025-10$0.00
$0.002025-09$0.00
$0.002025-08$0.00
$0.002025-07$0.00
$0.002025-06$24002
$650012025-05$73002
$1535052025-04$97502
$80012025-03$8001
$325012025-02$8001
$0.002025-01$0.00
$0.002024-12$0.00
DatePoliticianPartyChamberAmount ($)
Buy2025-06-23Ro KhannaDHouse$1,001 - $15,000
Buy2025-06-20Ro KhannaDHouse$1,001 - $15,000
Buy2025-06-20Ro KhannaDHouse$1,001 - $15,000
Sell2025-05-19Ro KhannaDHouse$15,001 - $50,000
Sell2025-05-16Rick W. AllenRHouse$15,001 - $50,000
Buy2025-05-15Rob BresnahanRHouse$15,001 - $50,000
Buy2025-05-13Markwayne MullinRSenate$15,001 - $50,000
Buy2025-05-05Thomas H. Kean, Jr.RHouse$1,001 - $15,000
Sell2025-04-21Bruce WestermanRHouse$1,001 - $15,000
Buy2025-04-15Ro KhannaDHouse$15,001 - $50,000
Buy2025-04-15Ro KhannaDHouse$15,001 - $50,000
Sell2025-04-11Dan NewhouseRHouse$1,001 - $15,000
Sell2025-04-11Rick W. AllenRHouse$15,001 - $50,000
Buy2025-04-09Ro KhannaDHouse$15,001 - $50,000
Sell2025-04-08Rob BresnahanRHouse$15,001 - $50,000
Sell2025-04-07Julie JohnsonDHouse$1,001 - $15,000
Sell2025-04-07Jefferson ShreveRHouse$15,001 - $50,000
Sell2025-04-04Ro KhannaDHouse$1,001 - $15,000
Sell2025-04-04Ro KhannaDHouse$1,001 - $15,000
Sell2025-04-04Ro KhannaDHouse$1,001 - $15,000
Sell2025-04-04Ro KhannaDHouse$1,001 - $15,000
Sell2025-03-27Greg LandsmanDHouse$1,001 - $15,000
Buy2025-03-03Bruce WestermanRHouse$1,001 - $15,000
Buy2025-02-25Ro KhannaDHouse$1,001 - $15,000
Sell2025-02-19Ro KhannaDHouse$15,001 - $50,000
Sell2024-11-15Ro KhannaDHouse$15,001 - $50,000

Tools

Dividend Income

Investment Amount
Dividend Yield
What is the Dividend Income Calculator?

The Dividend Income Calculator helps you estimate the yearly, quarterly, monthly, and daily income of your investments.

How to Use This Calculator?

Enter the dividend yield and the invested amount. Optionally, preload stock data to automatically fetch the dividend yield.

Required Investment

Dividend Yield
Desired Yearly Payout
Desired Quarterly Payout
Desired Monthly Payout
What is the Required Investment Calculator?

The Required Investment Calculator helps you determine the amount of money you need to invest in a stock to achieve a desired dividend.

How to Use This Calculator?

Enter the dividend yield and your desired dividend income. Optionally, preload stock data to automatically fetch the dividend yield.

Future Dividend Yield

Base Dividend
Current Price
Number of Years
Dividend Growth Rate
What is the Future Yield Calculator?

The Future Yield Calculator helps you estimate the future dividend yield of a stock based on its current dividend, price, and expected dividend growth rate.

How to Use This Calculator?

Enter the base dividend, current price, number of years, and dividend growth rate. Optionally, preload stock data to automatically fetch the dividend and price. The calculator will display the current yield and the projected future yield.

Future Dividend Income

Base Dividend
Number of Years
Dividend Growth Rate
What is the Future Dividend Income Calculator?

The Future Dividend Income Calculator helps you estimate the future dividend income from your investments based on the current dividend yield and expected growth rate.

How to Use This Calculator?

Enter the current dividend yield, expected growth rate, and investment duration. Optionally, preload stock data to automatically fetch the dividend yield.

(C) PEVALUATOR
About
Terms & privacy
Price charts & news courtesy of TradingView
Blog
Contact